272 related articles for article (PubMed ID: 33770574)
1. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Yang Y; Wang K; Chen H; Feng Z
Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
[TBL] [Abstract][Full Text] [Related]
4. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
6. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
7. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
[TBL] [Abstract][Full Text] [Related]
8. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold.
Qin M; Cao Q; Wu X; Liu C; Zheng S; Xie H; Tian Y; Xie J; Zhao Y; Hou Y; Zhang X; Xu B; Zhang H; Wang X
Eur J Med Chem; 2020 Jan; 186():111856. PubMed ID: 31734021
[TBL] [Abstract][Full Text] [Related]
10. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Dai X; Wang K; Chen H; Huang X; Feng Z
Bioorg Chem; 2021 Sep; 114():105034. PubMed ID: 34116264
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.
Song Z; Liu B; Peng X; Gu W; Sun Y; Xing L; Xu Y; Geng M; Ai J; Zhang A
J Med Chem; 2021 Nov; 64(22):16687-16702. PubMed ID: 34761679
[TBL] [Abstract][Full Text] [Related]
13. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Evaluation of
OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment.
Yang X; Cheng B; Xiao Y; Xue M; Liu T; Cao H; Chen J
Eur J Med Chem; 2021 Mar; 213():113058. PubMed ID: 33280898
[TBL] [Abstract][Full Text] [Related]
17. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Qin M; Meng Y; Yang H; Liu L; Zhang H; Wang S; Liu C; Wu X; Wu D; Tian Y; Hou Y; Zhao Y; Liu Y; Xu C; Wang L
J Med Chem; 2021 May; 64(9):5519-5534. PubMed ID: 33938739
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
